Company Overview
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on developing medicines for unmet medical needs in oncology, specifically targeting breast cancer and other conditions for women in the United States. The firm positions itself within the broader Healthcare sector, functioning specifically within the specialized Biotechnology industry, which implies a high degree of scientific risk and potential for significant innovation but also substantial regulatory hurdles before product commercialization. The company's current market capitalization stands at $40.65M, while its annual revenue and employee count are not disclosed in the available financial records. These valuation metrics indicate that Atossa Therapeutics is a small-cap entity, suggesting that the market assigns a relatively modest value to its pipeline assets compared to large-cap pharmaceutical peers, reflecting the early-stage nature of its clinical development efforts where revenue generation has not yet materialized at scale.
Financial Health
The company reports trailing twelve-month revenue of N/A, a net income of $-34,770,000, and an EBITDA of $-37,125,000, indicating that the firm is currently operating at a loss typical for clinical-stage biotechnology entities. The substantial gap between revenue, which is effectively non-existent in the current period, and the significant negative net income reveals a cost structure dominated by research and development expenditures rather than sales and marketing costs. Free cash flow is reported at $-20,878,124, which indicates that the company is consuming cash reserves to fund its operations and drug development programs rather than generating surplus liquidity. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which reflects a pre-revenue business model where traditional profitability metrics are not yet applicable until commercial sales commence. The company holds $41.30M in cash against N/A in debt, resulting in a debt-to-equity ratio of N/A, which suggests a conservative balance sheet with no reported leverage obligations to service. The current ratio stands at 5.53, indicating a strong short-term liquidity position where current assets significantly exceed current liabilities, providing ample buffer to sustain operations during the cash burn phase. Return on equity is -62.7% and return on assets is -37.4%, metrics that reveal the company is currently utilizing shareholder capital and assets to generate negative returns due to the heavy investment in clinical trials and pipeline advancement.
Valuation Assessment
The trailing P/E ratio is N/A due to the absence of positive earnings, while the forward P/E is listed as -1.61, a figure that implies the market is pricing the stock based on future expectations of earnings recovery or a specific accounting treatment for the projected negative earnings trajectory. The price-to-book ratio is 1.02, indicating that the market values the company's equity at approximately equal to its book value, which is often seen in clinical-stage companies where the intrinsic value of the drug pipeline is not yet fully reflected in the balance sheet assets. The price-to-sales ratio is N/A and the EV/EBITDA is 0.02, suggesting that traditional valuation multiples are less relevant than cash-based metrics for this stage of the company, though the low EV/EBITDA reflects the minimal enterprise value relative to its negative earnings. The stock's 52-week high is $19.35 and the 52-week low is $3.76, placing the current trading price within a wide volatility range that highlights the speculative nature of the asset. The beta value is N/A, meaning that the stock's price volatility relative to the broader market cannot be quantified using standard historical data, though the wide price range suggests high sensitivity to clinical trial updates and market sentiment.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet achieved commercial revenue milestones to establish a growth rate for comparison. Since the company has not generated positive earnings, the concept of earnings growing faster or slower than revenue does not currently apply, as the primary focus remains on capitalizing the pipeline rather than optimizing profit margins. Atossa Therapeutics does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which indicates that the company reinvests all available resources and retained earnings back into research, development, and clinical operations rather than distributing income to shareholders. The overall growth and income profile is characterized by a lack of current financial returns, with the company relying entirely on its cash reserves to fund future potential value creation from its oncology drug candidates.